Despite battling drugs from BridgeBio and Pfizer, Amvuttra beat Wall Street expectations with results Alnylam’s CEO claimed ...

Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $66.3 million in its second quarter. The Cambridge, Massachusetts-based company ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $406.0, a high ...

The better-than-expected launch of a rare heart disease drug pushed Alnylam (Nasdaq: ALNY) past the $50 billion market ...

Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 10 years ago, it would be worth $385.28 today based on a price of $433.41 for ALNY at the time of writing.

Q2 2025 Earnings Call Transcript July 31, 2025 Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.32, expectations were $-0.54371. Operator: Good morning, ladies and ...

Alnylam Pharmaceuticals (ALNY) shows strong price momentum, hitting new all-time highs on Aug. 11. ・ALNY has a 100% technical ...

10 analysts have expressed a variety of opinions on Alnylam Pharmaceuticals (NASDAQ:ALNY) over the past quarter, offering a diverse set of opinions from bullish to bearish. In the table below, you ...

Alnylam Pharmaceuticals's Current Market Status With a volume of 446,657, the price of ALNY is up 0.74% at $233.99. RSI indicators hint that the underlying stock may be oversold.

Morgan Stanley cut their price target on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an “equal weight” rating for the company in a report on Friday, April 11th.

Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 ...